Kazia Therapeutics (KZIA) Target Raised at Edison

October 13, 2021 11:29 AM EDT
Get Alerts KZIA Hot Sheet
Price: $10.50 --0%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 12 | New: 18
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Kazia Therapeutics (NASDAQ: KZIA) price target raised at Edison to A$2.83 per basic share, or ~$20.90 per ADR.

Analyst Maxim Jacobs commented, "Kazia expects to release multiple data points from its paxalisib programme in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed glioblastoma multiforme (GBM) patients, as well as initial data for paxalisib in the treatment of brain metastases (BMs). Additionally, the Phase I for EVT801 is expected to begin enrolment by year-end."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments